---
figid: PMC8663026__fonc-11-766298-g006
figtitle: Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor
  Tyrosine Kinase Driven Tumors
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8663026
filename: fonc-11-766298-g006.jpg
figlink: /pmc/articles/PMC8663026/figure/f6/
number: F6
caption: Model for combination benefit of vertical inhibition of PI3K/AKT/eIF4F pathway.
  Combined downregulation of AKT activity, RTK expression/activation and cyclin D1-dependent
  proliferation is effective in treatment of RTK-driven tumors. Left, in untreated
  RTK-driven cancer cells, hyperactivation of eIF4A sustains expression of oncogenic
  RTKs and cyclin D1. Center, treatments targeted at PI3K/AKT inhibition are limited
  by relief of feedback loops that induce RTKs activation (). Right, combination of
  PI3K/AKT inhibitors with zotatifin reduce undesired RTK activation, while maintaining
  low AKT activity and low expression of oncogenic cyclin D1.
papertitle: Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor
  Tyrosine Kinase Driven Tumors.
reftext: Adina Gerson-Gurwitz, et al. Front Oncol. 2021;11:766298.
year: '2021'
doi: 10.3389/fonc.2021.766298
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: zotatifin | eIF4A | PI3K | AKT | mTOR | receptor tyrosine kinase | RTK
automl_pathway: 0.923994
figid_alias: PMC8663026__F6
figtype: Figure
redirect_from: /figures/PMC8663026__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8663026__fonc-11-766298-g006.html
  '@type': Dataset
  description: Model for combination benefit of vertical inhibition of PI3K/AKT/eIF4F
    pathway. Combined downregulation of AKT activity, RTK expression/activation and
    cyclin D1-dependent proliferation is effective in treatment of RTK-driven tumors.
    Left, in untreated RTK-driven cancer cells, hyperactivation of eIF4A sustains
    expression of oncogenic RTKs and cyclin D1. Center, treatments targeted at PI3K/AKT
    inhibition are limited by relief of feedback loops that induce RTKs activation
    (). Right, combination of PI3K/AKT inhibitors with zotatifin reduce undesired
    RTK activation, while maintaining low AKT activity and low expression of oncogenic
    cyclin D1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1S1
  - MTOR
  - RPTOR
  - EIF4B
  - EIF4A1
  - EIF4A2
  - EIF4A3
  - EIF4G1
  - EIF4G2
  - EIF4G3
  - CCND1
  - AKT1
  - AKT2
  - AKT3
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - Tie
  - Ras85D
  - InR
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - PRAS40
  - Crtc
  - eIF4B
  - CG9932
  - eIF4A
  - CG7483
  - eIF4G2
  - eIF4G1
  - Akt
  - foxo
---
